Analyst Ratings February 25, 2026

H.C. Wainwright Lowers Day One Biopharmaceuticals Price Target to $22 While Keeping Buy Rating

Analyst trims target amid sustained commercial momentum for OJEMDA as the company advances multiple ADC programs toward mid-2026 readouts

By Jordan Park DAWN
H.C. Wainwright Lowers Day One Biopharmaceuticals Price Target to $22 While Keeping Buy Rating
DAWN

H.C. Wainwright cut its price target on Day One Biopharmaceuticals to $22 from $25 but left its Buy rating intact. The biotech, valued at $1.23 billion, posted strong commercial performance for OJEMDA in 2025 and reiterated 2026 revenue guidance as it progresses a pipeline of antibody-drug conjugates with data and enrollment milestones expected through 2027.

Key Points

  • H.C. Wainwright lowered its price target on Day One Biopharmaceuticals to $22 from $25 but kept a Buy rating.
  • Day One reported full-year 2025 OJEMDA net product revenue of $155.4 million (172% YoY growth) and Q4 revenue of $52.8 million; gross margins are 89%.
  • Pipeline and clinical milestones include emiltatug ledadotin Phase 1 data expected mid-2026, DAY301 initial data in H2 2026, and FIREFLY-2 enrollment completion in H1 2026 with topline in mid-2027.

Analyst action

H.C. Wainwright reduced its price target on Day One Biopharmaceuticals (NASDAQ: DAWN) to $22 from $25 while maintaining a Buy recommendation on the shares. The firm’s adjustment comes as investors track both the commercial rollout of OJEMDA and a slate of clinical-readout milestones the company has scheduled through 2027.


Market context and valuation

Day One is currently valued at approximately $1.23 billion. Over the past six months the stock has climbed roughly 72%, with sell-side targets observed in a range from $17 to $29. These targets reflect differing analyst views on commercialization trajectory and pipeline progress.


Commercial performance

The company reported full-year 2025 net product revenue of $155.4 million for OJEMDA, representing 172% year-over-year growth after the drug’s April 2024 approval for relapsed/refractory BRAF-altered pediatric low-grade glioma. Quarterly momentum continued into the fourth quarter, when revenue reached $52.8 million, supported by rising prescription volumes and growing familiarity among treating physicians.

Prescription data show 1,394 prescriptions in the fourth quarter and a total of 4,635 prescriptions for 2025, an increase of 181% versus 2024. The business unit sustained an 89% gross profit margin, a metric that highlights the product’s current pricing strength.


Guidance and analyst comparisons

Day One reaffirmed its U.S. revenue guidance for fiscal 2026 at $225 million to $250 million. The midpoint of that guidance modestly exceeds the analyst consensus of $236.6 million. In the latest quarter the company’s $52.8 million in revenue also topped the analyst estimate of $45.86 million.


Clinical development and milestones

On the clinical front, updated long-term follow-up from the pivotal FIREFLY-1 trial reported a 53% objective response rate, a median duration of response of 19.4 months, and a median time to next treatment of 42.6 months.

Day One has been active on the acquisition and advancement front. It acquired emiltatug ledadotin, a B7-H4-targeted antibody-drug conjugate (ADC) currently in Phase 1 for adenoid cystic carcinoma, with data anticipated in mid-2026. The company is also advancing DAY301, a PTK7-targeted ADC, and expects initial clinical data in the second half of 2026.

Enrollment in the Phase 3 FIREFLY-2 frontline pediatric low-grade glioma trial is expected to complete in the first half of 2026, with topline results projected for mid-2027.


What this means for investors

The analyst adjustment to the price target reflects updated expectations for valuation while leaving the investment rating unchanged. Key commercial metrics and upcoming clinical readouts will likely remain focal points for market participants as they reassess revenue trajectories and pipeline de-risking over the next 12 to 24 months.

Risks

  • Timing risk around clinical data readouts and trial enrollment - delays could affect pipeline valuation and investor sentiment (impacts biotech and healthcare sectors).
  • Commercial execution risk tied to continued prescription growth and physician uptake for OJEMDA - slowing demand could alter revenue trajectory (impacts pharma and healthcare markets).
  • Market and analyst variability risk - changes in analyst targets or market valuation could influence share performance despite current guidance (impacts capital markets and biotech investment flows).

More from Analyst Ratings

RBC Keeps AMD at Sector Perform, Sees Meta Agreement as Strategic Upside Despite Warrants Feb 25, 2026 KeyBanc Lifts Elanco Price Target as Product Momentum Strengthens Heading into 2026 Feb 25, 2026 Morgan Stanley Begins Coverage of Flywire, Sets $15 Price Target Feb 25, 2026 KeyBanc Keeps Overweight on Addus After Q4 Beat; Valuation and M&A Outlook Highlighted Feb 25, 2026 KeyBanc Sticks With Overweight on Revolve, Cites Early-2026 Momentum Feb 25, 2026